Prognostic significance of interleukin 17 in cancer: A meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 10, 2014, Pages 3258-3269

  Zhang, Xiao ^a   Weng, Wenhao ^a   Xu, Wen ^b   Wang, Yulan ^a   Yu, Wenjun ^a   Tang, Xun ^a   Ma, Lifang ^a   Pan, Qiuhui ^a   Wang, Jiayi ^a   Sun, Fenyong ^a  

^a TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

IL 17; Meta analysis; Prognosis; Survival

Indexed keywords

INTERLEUKIN 17;

ARTICLE; CANCER PROGNOSIS; CELL HETEROGENEITY; DISEASE FREE SURVIVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HAZARD RATIO; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; STOMACH CANCER;

EID: 84910027164     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Kuschel B, Auranen A, McBride S, Novik KL, Antoniou A, Lipscombe JM, Day NE, Easton DF, Ponder BA, Pharoah PD and Dunning A. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet 2002; 11: 1399-1407.
2. Gansler T, Ganz PA, Grant M, Greene FL, Johnstone P, Mahoney M, Newman LA, Oh WK, Thomas CR Jr, Thun MJ, Vickers AJ, Wender RC and Brawley OW. Sixty years of CA: a cancer journal for clinicians. CA Cancer J Clin 2010; 60: 345-350.
3. Paul D, Kumar A, Gajbhiye A, Santra MK and Srikanth R. Mass spectrometry-based proteomics in molecular diagnostics: discovery of cancer biomarkers using tissue culture. Biomed Res Int 2013; 2013: 783131.
4. Zhang CH, Xu GL, Jia WD, Ge YS, Li JS, Ma JL and Ren WH. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer 2012; 130: 2685-2692.
5. Peng Z, Zhu Y, Wang Q, Gao J, Li Y, Li Y, Ge S and Shen L. Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis. PLoS One 2014; 9: e84502.
6. Chen J, Zhou J, Lu J, Xiong H, Shi X and Gong L. Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis. BMC Cancer 2014; 14: 15.
7. Rouvier E, Luciani MF, Mattei MG, Denizot F and Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 1993; 150: 5445-5456.
8. Iwakura Y, Ishigame H, Saijo S and Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011; 34: 149-162.
9. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q and Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6: 1133-1141.
10. Weaver CT, Hatton RD, Mangan PR and Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25: 821-852.
11. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008; 8: 337-348.
12. Murugaiyan G and Saha B. Protumor vs antitumor functions of IL-17. J Immunol 2009; 183: 4169-4175.
13. Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB and Drake CG. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 2008; 14: 3254-3261.
14. Le Gouvello S, Bastuji-Garin S, Aloulou N, Mansour H, Chaumette MT, Berrehar F, Seikour A, Charachon A, Karoui M, Leroy K, Farcet JP and Sobhani I. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008; 57: 772-779.
15. Zhu X, Mulcahy LA, Mohammed RA, Lee AH, Franks HA, Kilpatrick L, Yilmazer A, Paish EC, Ellis IO, Patel PM and Jackson AM. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res 2008; 10: R95.
16. Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, Zhu B and Chen Z. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 2010; 69: 348-354.
17. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP and Zheng L. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009; 50: 980-989.
18. Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J and Wang RF. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A 2008; 105: 15505-15510.
19. Du JW, Xu KY, Fang LY and Qi XL. Interleukin-17, produced by lymphocytes, promotes tumor growth and angiogenesis in a mouse model of breast cancer. Mol Med Rep 2012; 6: 1099-1102.
20. Jovcic G, Bugarski D, Krstic A, Vlaski M, Petakov M, Mojsilovic S, Stojanovic N and Milenkovic P. The effect of interleukin-17 on hematopoietic cells and cytokine release in mouse spleen. Physiol Res 2007; 56: 331-339.
21. Santos JI, Teixeira AL, Dias F, Mauricio J, Lobo F, Morais A and Medeiros R. Influence of peripheral whole-blood microRNA-7 and microRNA-221 high expression levels on the acquisition of castration-resistant prostate cancer: evidences from in vitro and in vivo studies. Tumour Biol 2014; 35: 7105-13.
22. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M and Tugwell P. The newcastle-ottawa scale (nos) for assessing the quality of nonrandomized studies in meta-analyses. 2011; Available: www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
23. Chen JG, Xia JC, Liang XT, Pan K, Wang W, Lv L, Zhao JJ, Wang QJ, Li YQ, Chen SP, He J, Huang LX, Ke ML, Chen YB, Ma HQ, Zeng ZW, Zhou ZW, Chang AE and Li Q. Intratumoral expression of IL-17 and its prognostic role in gastric adenocarcinoma patients. Int J Biol Sci 2011; 7: 53-60.
24. He S, Fei M, Wu Y, Zheng D, Wan D, Wang L and Li D. Distribution and clinical significance of th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients. Int J Mol Sci 2011; 12: 7424-7437.
25. Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, Lin Z and Zhu B. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 2011; 407: 348-354.
26. Lv L, Pan K, Li XD, She KL, Zhao JJ, Wang W, Chen JG, Chen YB, Yun JP and Xia JC. The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma. PLoS One 2011; 6: e18219.
27. Gu FM, Gao Q, Shi GM, Zhang X, Wang J, Jiang JH, Wang XY, Shi YH, Ding ZB, Fan J and Zhou J. Intratumoral IL-17(+) cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma. Ann Surg Oncol 2012; 19: 2506-2514.
28. Jain P, Javdan M, Feger FK, Chiu PY, Sison C, Damle RN, Bhuiya TA, Sen F, Abruzzo LV, Burger JA, Rosenwald A, Allen SL, Kolitz JE, Rai KR, Chiorazzi N and Sherry B. Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica 2012; 97: 599-607.
29. Liu T, Peng L, Yu P, Zhao Y, Shi Y, Mao X, Chen W, Cheng P, Wang T, Chen N, Zhang J, Liu X, Li N, Guo G, Tong W, Zhuang Y and Zou Q. Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer. J Clin Immunol 2012; 32: 1332-1339.
30. Wu J, Du J, Liu L, Li Q, Rong W, Wang L, Wang Y, Zang M, Wu Z, Zhang Y and Qu C. Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy. PLoS One 2012; 7: e50035.
31. Zhang GQ, Han F, Fang XZ and Ma XM. CD4+, IL17 and Foxp3 Expression in Different pTNM Stages of Operable Non-small Cell Lung Cancer and Effects on Disease Prognosis. Asian Pac J Cancer Prev 2012; 13: 3955-3960.
32. Zhuang Y, Peng LS, Zhao YL, Shi Y, Mao XH, Chen W, Pang KC, Liu XF, Liu T, Zhang JY, Zeng H, Liu KY, Guo G, Tong WD, Shi Y, Tang B, Li N, Yu S, Luo P, Zhang WJ, Lu DS, Yu PW and Zou QM. CD8(+) T cells that produce interleukin-17 regulate myeloid-derived suppressor cells and are associated with survival time of patients with gastric cancer. Gastroenterology 2012; 143: 951-962, e958.
33. Chen WC, Lai YH, Chen HY, Guo HR, Su IJ and Chen HH. Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. Histopathology 2013; 63: 225-233.
34. Cui X, Xu Z, Zhao Z, Sui D, Ren X, Huang Q, Qin J, Hao L, Wang Z, Shen L and Lin S. Analysis of CD137L and IL-17 expression in tumor tissue as prognostic indicators for gliblastoma. Int J Biol Sci 2013; 9: 134-141.
35. Lan C, Huang X, Lin S, Huang H, Cai Q, Lu J and Liu J. High density of IL-17-producing cells is associated with improved prognosis for advanced epithelial ovarian cancer. Cell Tissue Res 2013; 352: 351-359.
36. Liao R, Sun J, Wu H, Yi Y, Wang JX, He HW, Cai XY, Zhou J, Cheng YF, Fan J and Qiu SJ. High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma. J Exp Clin Cancer Res 2013; 32: 3.
37. Wang B, Li L, Liao Y, Li J, Yu X, Zhang Y, Xu J, Rao H, Chen S, Zhang L and Zheng L. Mast cells expressing interleukin 17 in the muscularis propria predict a favorable prognosis in esophageal squamous cell carcinoma. Cancer Immunol Immunother 2013; 62: 1575-1585.
38. Wu D, Wu P, Huang Q, Liu Y, Ye J and Huang J. Interleukin-17: a promoter in colorectal cancer progression. Clin Dev Immunol 2013; 2013: 436307.
39. Gabrilovich DI and Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174.
40. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V and Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 64: 6337-6343.
41. Novitskiy SV, Pickup MW, Gorska AE, Owens P, Chytil A, Aakre M, Wu H, Shyr Y and Moses HL. TGF-beta receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms. Cancer Discov 2011; 1: 430-441.
42. Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, Sandoval F, Quintin-Colonna F, Lacerda K, Karadimou A, Badoual C, Tedgui A, Fridman WH and Oudard S. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011; 30: 83-95.
43. Ersvaer E, Melve GK and Bruserud O. Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation? Cancer Immunol Immunother 2011; 60: 1669-1681.
44. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautes-Fridman C, Fossiez F, Haicheur N, Fridman WH and Tartour E. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002; 99: 2114-2121.
45. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R and Zou W. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009; 114: 1141-1149.
46. Li J, Lau GK, Chen L, Dong SS, Lan HY, Huang XR, Li Y, Luk JM, Yuan YF and Guan XY. Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS One 2011; 6: e21816.
47. Gu FM, Li QL, Gao Q, Jiang JH, Zhu K, Huang XY, Pan JF, Yan J, Hu JH, Wang Z, Dai Z, Fan J and Zhou J. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Mol Cancer 2011; 10: 150.
48. Tung-Ping Poon R, Fan ST and Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232: 10-24.
49. Zhang GQ, Han F, Fang XZ and Ma XM. [Expression of CD4(+) and IL-17, Foxp3 in non-small cell lung cancer and their correlation with microvessel density]. Zhonghua Zhong Liu Za Zhi 2012; 34: 596-599.
50. Chen X, Xie Q, Cheng X, Diao X, Cheng Y, Liu J, Xie W, Chen Z and Zhu B. Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: Enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells. Cancer Sci 2010; 101: 2384-2390.
51. Xu C, Hao K, Yu L and Zhang X. Serum interleukin-17 as a diagnostic and prognostic marker for non-small cell lung cancer. Biomarkers 2014; 19: 287-90.
52. Lu L, Pan K, Zheng HX, Li JJ, Qiu HJ, Zhao JJ, Weng DS, Pan QZ, Wang DD, Jiang SS, Chang AE, Li Q and Xia JC. IL-17A promotes immune cell recruitment in human esophageal cancers and the infiltrating dendritic cells represent a positive prognostic marker for patient survival. J Immunother 2013; 36: 451-458.
53. Zhao Q, Xiao X, Wu Y, Wei Y, Zhu LY, Zhou J and Kuang DM. Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients. Eur J Immunol 2011; 41: 2314-2322.
54. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK and Sasaki H. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005; 175: 6177-6189.
55. Li Q, Han Y, Fei G, Guo Z, Ren T and Liu Z. IL-17 promoted metastasis of non-small-cell lung cancer cells. Immunol Lett 2012; 148: 144-150.